A new study indicates that the Xarelto and Eliquis reversal agent Andexxa restores 82% of patients to excellent or good hemostasis following a major bleeding event caused by the blood…
The FDA is calling for clinical trials before it will approve the long-delayed Xarelto and Eliquis reversal agent, AndexXa.
Some doctors are expressing concerns about the safety and efficacy of a proposed reversal agent for the blood thinners Eliquis and Xarelto.
A proposed reversal agent for Xarelto and Eliquis stopped 79% of bleeding events suffered by patients after receiving the drugs, according to the findings of a new study.
A proposed reversal agent for the blood thinners Xarelto and Eliquis suffered a setback this week when the FDA rejected its approval, asking questions about manufacturing and its potential use…
The FDA may soon be asked to approve a reversal agent for the blood thinner Xarelto, which has been linked to uncontrollable bleeding events.
